We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genotyping Assay Integrated into Glioma Treatment

By LabMedica International staff writers
Posted on 22 Aug 2018
Stage II diffuse gliomas are normally challenging to identify using intraoperative histologic methods because of their location, infiltrative growth, low cellularity, and small stereotactic biopsy size. More...
Diagnosis often requires the patient to undergo multiple neurosurgical procedures to collect tumor tissue samples.

A rapid multiplexed polymerase chain reaction (PCR)-based genotyping tool has been developed to diagnose patients with a mutated brain tumor cell line during surgery, which could be used in tandem with a therapeutic tool to eradicate the glioma. Lower-grade gliomas are often characterized by mutations in metabolism-related genes isocitrate dehydrogenase 1 (IDH1) and IDH2.

A large team of scientists led by those at the Harvard Medical School (Boston, MA, USA) first characterized the patterns of IDH mutant glioma progression by analyzing a cohort of 130 patients who underwent resection. Afterwards, they integrated the genotyping tool with the drug delivery system on glioma tissue samples resected from neurosurgery operations to develop a prototype for the proposed combined surgical model. By suppressing wild-type alleles, the team detected mutations in IDH1, Telomerase Reverse Transcriptase (TERT) promoter mutations, H3 Histone Family Member 3A (H3F3A), and BRAF within 27 minutes.

The team then validated the genetic diagnostic tool on extracted human samples, testing the assay on 87 clinically annotated brain tumors. They found that the presence of at least one or more mutations in captured 75 brain tumor samples, noting in their paper that the high rate of positive assignment allows for the confidence to distinguish tumor versus nonneoplastic pathologies.

Daniel P. Cahill, MD, PhD, a neurology associate professor and senior author of the study, said, “We have found that a high frequency of cases can be classified correctly by scoring a handful of these point mutations. We suggested an opportunity, where we could, through an optimized PCR technique, prove a clinically useful categorizing technology in a rapid way.” The continuation study was published on August 6, 2018, in the journal Proceedings of National Academy of Sciences.

Related Links:
Harvard Medical School


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.